Application of immunohistochemistry in clinical practice: A review

East African Medical Journal

Volumn 84, Issue 8, 2007, Pages 389-397

  Kalebi, A Y ^a,b,e   Dada, M A ^c,d  

^a BDIAP ^*

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Withybush General Hospital   (United Kingdom)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; NEOPLASM; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 35248885323     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Leong A.S. and Leong T.Y. Newer developments in immunohistology. J. Clin. Pathol. 2006; 59:1117-1126.
2. Kremer M., Quintanilla-Martinez L., Nabrig J., et al. IHC in bone marrow pathology: A useful adjunct for morphologic diagnosis. Virchows Arch. 2005; 447: 920-937.
3. Warner S. Diagnostics + Therapy = Theranostics. The Scientist 2004,18(16):38. (www.thescientist.com/200418130). Accessed on November 22nd, 2006.
4. Immunoperoxidase versus immunofluorescence in the assessment of human renal biopsies. Amer. J. Kidney Dis. 2005; 45: 674-683.
5. Zuber C., Fan J., Guhl B. and Roth J. Applications of immunogold labeling in ultrastructural pathology. Ultrastruct. Pathol. 2005; 29:319-330.
6. Netto G.J. and Saad R.D. Diagnostic molecular pathology: an increasingly indispensable tool for the practicing pathologist. Arch. Pathol. Lab. Med. 2006; 130: 1339-1348.
7. Burg G., Kempf W., Cozzio A., Feit J., et al. WHO/EORTC classification of cutaneous lymphomas 2005: Histological and molecular aspects. J. Cutan. Pathol. 2005; 32: 647-674.
8. Fletcher CD. The evolving classification of soft tissue tumours: An update based on the new WHO classification. Histopathol. 2006; 48:3-12.
9. Orem J., Otieno M.W. and Remick S.C. Challenges and opportunities for treatment and research of AIDSrelated malignancies in Africa. Curr. Opi'n. Oncol. 2006; 18:479-486.
10. Gavilondo J.V. and Larrick J.W. Antibody engineering at the millennium. Biotechniques 2000; 29:128-132, 134-136, 138.
11. Hasui K., Takatsuka T., Sakamoto R., et al. Improvement of supersensitive immunohistochemistry with an autostainer: A simplified catalysed signal amplification system. Histochem. J. 2002; 34:215-222.
12. Eguiluz C., Viguera E., Millan L. and Perez J. Multitissue array review: A chronological description of tissue array techniques, applications and procedures. Pathol. Res. Pract. 2006; 202:561-568.
13. Yaziji H. and Barry T. Diagnostic IHC: What can go wrong? Adv. Anat. Pathol. 2006; 13:238-246.
14. Sompuram S.R., Vani K., Hafer U., et al. Antibodies immunoreactive with formalin-fixed tissue antigens recognise linear protein epitopes. Amer. J. Clin. Pathol. 2006; 125:82-90.
15. Barker P.E. Cancer biomarker validation: standards and process: Roles for the National Institute of Standards and Technology (NIST). Ann. N. Y. Acad. Sci. 2003; 983:142-150.
16. Pathologyoutlines.com® (www.pathologyoutlines.com) last accessed on November 25, 2006.
17. Immunoquery.com® (www.ipox.org) last accessed on November 25, 2006.
18. Rosai J. Special techniques in surgical pathology. In: Rosai and Ackerman's surgical pathology 8th. ed. Vol. 1. London, Mosby, 2004; 45-63.
19. Zhou M., Shah R., Shen R. and Rubin MA. Basal cell cocktail (34âE12 + p63) improves the detection of prostate basal cells. Amer. J. Surg. Pathol. 2003; 27: 365-371.
20. Yin H. and Leong AS. Histologic grading of noninvasive papillary urothelial: Validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Amer. J. Clin. Pathol. 2004; 121:679-687.
21. Sun W. and Herrera G.A. E-cadherin expression in invasive urothelial carcinoma. Ann. Diagn. Pathol. 2004; 8: 17-22.
22. Moriya T., Kasajima A., Ishida K., et al. New trends of IHC for making differential diagnosis of breast lesions. Med. Mol. Morphol. 2006; 39:8-13.
23. Becher M.W., Abel T.W., Thompson R.C., et al. Immunohistochemical analysis of metastatic neoplasms of the central nervous system. J. Neuropathol. Exp. Neurol. 2006; 65:935-944.
24. Reifenberger G. and Collins V.P. Pathology and molecular genetics of astrocytic gliomas. J. Mol. Med. 2004; 82:656-670.
25. Koperek O., Gelpi E., Birner P., et al. Value and limits of IHC in differential diagnosis of clear cell primary brain tumours. Acta. Neuropathol. (Berl). 2004; 108:24-30.
26. Vege K.D., Giannini C. and Scheithauer B.W. The immunophenotype of ependymomas. Appl. Immunohistochem. Mol. Morphol. 2000; 8:25-31.
27. Preusser M., Laggner U., Haberler C., et al. Comparative analysis of NeuN immunoreactivity in primary brain tumours: Conclusions for rational use in diagnostic histopathology. Histopathol. 2006; 48:438-444.
28. Marjoniemi V.M. Immunohistochemistry in gynaecological pathology: A review. Pathol. 2004; 36: 109-119.
29. Slater D.N. The new WHO-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: A practical marriage of two giants. Brit. J. Dermatol. 2005; 153:874-880.
30. Liang P., Nakada I., Hong J.W., et al. Prognostic significance of immunohistochemically detected blood and lymphatic vessel invasion in colorectal carcinoma: Its impact on prognosis. Ann. Surg. Oncol. 2006; 14: 10.1245/s 10434-006-9189-3 (Online version ahead of print accessed on 19th November 2006).
31. de Wit N.J., van Muijen G.N. and Ruiter D.J. Immunohistochemistry in melanocytic proliferative lesions. Histopathol. 2004; 44:517-541.
32. Busam K.J. The use and application of special techniques in assessing melanocytic tumours. Pathol. 2004; 36:462-469.
33. Ordonez N.G. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Human Pathol. 2007; 38:1-16.
34. Rush D., Hyjek E., Baergen R.N., et al. Detection of microinvasion in vulvar and cervical intraepithelial neoplasia using double immunostaining for cytokeratin and basement membrane components. Arch. Pathol. Lab. Med. 2005; 129: 747-753.
35. Wick M.R. Immunohistology of neuroendocrine and neuroectodermal tumours. Semin. Diagn. Pathol. 2000; 17:194-203.
36. Erlandson R.A. and Antonescu C.R. The rise and fall of malignant fibrous histiocytoma. Ultrastruct. Pathol. 2004; 28: 283-289.
37. Tos A.P. Classification of pleomorphic sarcomas: where are we now? Histopathol. 2006; 48: 51-62.
38. Kontogeorgos G. Classification and pathology of pituitary tumors. Endocrine. 2005; 28:27-35.
39. Hameed O. and Humphrey P.A. IHC in diagnostic surgical pathology of the prostate. Semin. Diagn. Pathol. 2005; 22:88-104.
40. Morotti R.A., Nicol K.K., Parham D.M., et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: The children's oncology group experience. Amer. J. Surg. Pathol. 2006; 30: 962-968.
41. Fisher C The comparative roles of electron microscopy and IHC in the diagnosis of soft tissue tumours. Histopathol. 2006; 48:32-41.
42. Coindre J.M. IHC in the diagnosis of soft tissue tumours. Histopathol. 2003; 43:1-16.
43. Emerson R.E. and Ulbright T.M. The use of IHC in the differential diagnosis of tumours of the testis and paratestis. Semin. Diagn. Pathol. 2005; 22:33-50.
44. Suster S. Thymic carcinoma: update of current diagnostic criteria and histologic types. Semin. Diagn. Pathol. 2005; 22:198-212.
45. Asa SL. The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr. Pathol. 2005; 16:295-309.
46. Al-Brahim N. and Asa S.L. Papillary thyroid carcinoma: an overview. Arch. Pathol. Lab. Med. 2006; 130: 1057-1062.
47. Nuovo G.J. The surgical and cytopathology of viral infections: utility of IHC, in situ hybridisation, and in situ polymerase chain reaction amplification. Ann. Diagn. Pathol. 2006; 10: 117-131.
48. Davis GG. Malpractice in pathology: What to do when you are sued. Arch. Pathol. Lab. Med. 2006; 130: 975-978.
49. Dionisio D., Cao Y., Hongzhou L., et al. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios? Curr. HIV Res. 2006; 4:3-20.